Accuray Incorporated (ARAY) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals a decline in net and product revenues, a significant drop in gross margins, and an increased operating loss. Despite a strong order backlog and stable cash position, geopolitical issues in key markets and unclear management responses in the Q&A section contribute to negative sentiment. The guidance suggests a back-loaded fiscal year, but current challenges overshadow potential future improvements. The lack of clarity in management's answers, particularly regarding tariffs and order cancellations, further exacerbates concerns, leading to an overall negative outlook for stock price movement.
Key Financial Performance
Net Revenue $94 million, down 7% year-over-year and down 9% on a constant currency basis. The decline was attributed to slower performance in the EIMEA and China regions.
Product Revenue $37 million, down 23% year-over-year and down 24% on a constant currency basis. The decline was mainly due to slower performance in the EIMEA and China regions.
Service Revenue $57 million, up 7% year-over-year and up 4% on a constant currency basis. The increase was driven by contract revenue growth of 10% year-over-year, which outpaced the installed base growth of 2%, illustrating the impact of pricing actions.
Order Backlog Approximately $396 million, representing over 18 months of product revenue. This provides strong visibility and confidence in future revenue conversion.
Overall Gross Margin 28.3%, compared to 33.9% in the prior year. The decline was primarily driven by product gross margins, which were impacted by sales mix, incremental costs associated with tariffs, and a one-time obsolescence charge.
Product Gross Margin 20.3%, compared to 32.9% in the prior year. The decline was due to unfavorable sales mix ($2.9 million or 7.8 points), incremental tariff costs ($1.1 million or 3 points), and a one-time obsolescence charge ($0.7 million or 1.7 points).
Service Gross Margin 33.5%, 1.4 points lower than the prior year. The decline was primarily driven by lower parts consumption in Q1 of fiscal year '25 due to a supplier credit obtained in that quarter.
Operating Expenses $37.9 million, compared to $36.6 million in the prior year. The increase was largely due to $3.3 million in restructuring and post-financing costs, partially offset by $1 million of realized savings from restructuring actions.
Operating Loss $11.3 million, compared to a loss of $2.1 million in the prior year. The increase in loss was due to product gross margin challenges and restructuring costs.
Adjusted EBITDA Loss of $4.1 million, compared to an income of $3.1 million in the prior year. This was largely due to product gross margin challenges.
Cash, Cash Equivalents, and Short-term Restricted Cash $64 million, up from $57 million at the end of the prior quarter. The increase was primarily due to a net decrease in primary working capital.
Net Accounts Receivable $54 million, down $29 million from the prior quarter. The decrease was due to lower revenues and collection of certain past due receivables.
Net Inventory Balance $156 million, up $14 million from the prior quarter. The increase was due to ramping up for increased manufacturing in the coming quarters.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Stellar product launch: Accuray launched the Stellar product at ASTRO, emphasizing its commitment to adaptive radiotherapy and precision care. The product received strong interest from both existing and new customers.
Global adoption and partnerships: Accuray signed a memorandum of understanding with the University of Wisconsin School of Medicine and Public Health to advance adaptive radiotherapy. Additionally, the first patients were treated in Melbourne, Australia using the CyberKnife system, addressing unmet cancer needs in the region.
Service revenue growth: Service revenue increased by 7% year-over-year, driven by contract revenue growth of 10% and pricing actions.
Restructuring plan: The company initiated a restructuring plan to reduce costs, align resources with strategic priorities, and streamline operations, resulting in $2.8 million in restructuring charges.
Transformation plan: Accuray is implementing a transformation plan to enhance competitiveness, drive margin expansion, and achieve sustainable growth. The plan includes achieving a high single-digit adjusted EBITDA margin within 12 months and double-digit margins in the medium to long term.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Net revenue for the first quarter was $94 million, down 7% year-over-year and 9% on a constant currency basis. Product revenue was particularly weak, down 23% year-over-year, driven by slower performance in EIMEA and China regions.
Gross Margin Decline: Overall gross margin for the quarter declined to 28.3% from 33.9% in the prior year. Product gross margins were significantly impacted by unfavorable sales mix, tariffs, and a one-time obsolescence charge.
Geopolitical and Macroeconomic Uncertainties: Ongoing geopolitical and macroeconomic uncertainties were mentioned as factors that could impact revenue and adjusted EBITDA guidance.
Restructuring Costs: The company incurred $2.8 million in restructuring charges, including $1.5 million in severance-related costs and $1.3 million in consulting costs, which impacted operating expenses and financial results.
Order Backlog and Timing Issues: Gross orders were lower than expected due to timing issues in customer orders, particularly in China and the Americas, affecting the order backlog and future revenue visibility.
Service Gross Margin Pressure: Service gross margins declined by 1.4 points year-over-year, driven by lower parts consumption and the absence of a supplier credit obtained in the prior year.
Inventory Build-Up: Net inventory balance increased by $14 million from the prior quarter, indicating potential inefficiencies or challenges in inventory management as the company ramps up manufacturing.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Adjusted EBITDA Margin: The company expects to reach a high single-digit adjusted EBITDA margin as a percentage of revenue on a run rate basis within 12 months. Over the medium to long term, the company aims to expand this margin to double digits.
Fiscal Year 2026 Revenue and Adjusted EBITDA Guidance: Revenue is projected to be in the range of $471 million to $485 million, with adjusted EBITDA expected to range between $31 million and $35 million.
Transformation Plan Impact: The transformation plan is expected to meaningfully improve adjusted EBITDA as a percentage of revenue, with more details to be provided in the fiscal Q2 earnings call.
Revenue Growth Outlook: Despite a slower-than-anticipated start in Q1, the company remains confident in achieving its fiscal year 2026 revenue guidance.
Future Earnings Momentum: The company anticipates increased earnings momentum going into fiscal year 2027, even amidst ongoing geopolitical and macroeconomic uncertainties.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the current state of the capital equipment purchasing and ordering environment across various regions?
A:The environment varies by region. There was a slowdown in EIMEA and China due to geopolitical and macro issues, which are starting to ease. The U.S. market is stable, and there is growth in the APAC region. The company is working with regional teams to better understand the capital equipment landscape for fiscal year '26.
Q:Why was there a significant difference between gross orders and net orders this quarter?
A:The difference was primarily due to timing of customer receipts in the Americas and China. Gross orders globally amounted to $40 million, which was lower than expected. While there were cancellations, they were not unusual.
Q:What updates are there on tariff mitigation efforts?
A:The company is actively using the duty drawback program to recover tariffs on equipment not remaining in the U.S. They are also considering implementing a foreign trade zone, though the tariff environment remains fluid. The company is closely monitoring the situation.
Q:What is the revenue split expectation for the first and second halves of the fiscal year?
A:The company expects first-half revenue to be about 40% of the full-year guidance and second-half revenue to be about 60%, due to product demand shifting to the second half. This is a change from the previous 45-55 split.
Q:How are product and geography mix impacting product gross margins, and what is the outlook?
A:Product and geography mix led to lower gross margins in Q1, with more deals in emerging markets. This trend is expected to continue in Q2 but improve in the second half as the backlog with better-margin developed market deals is executed. The service business grew by 7%, and contract revenue grew by 10%, which supports overall margin improvement.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the cancellations and age-outs related to net orders, using vague language to describe the situation. Additionally, while discussing tariff mitigation efforts, the response lacked clarity on the timeline or likelihood of implementing a foreign trade zone.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASTRO interest
ASTRO product
Analysis obligation
Australia CyberKnife
Australia community
Biologics Globus
Bone Biologics
CEO dedication
CEO role
China Americas
CyberKnife system
Diagnostics Medtronic
LaNeve
Stephen
belief
cancer
charge
commitment
company
culture
delivery
detail transformation
digit
experience
level
loss
margin expansion
margin percentage
patient life
precision
quality backlog
radiation
radiotherapy
resource
restructuring
technology
transformation plan
week
ARAY Transcript
Accuray Incorporated (ARAY) Q3 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary shows strong financial performance with increased revenue, gross margin, and net income, which is positive. However, the lack of strategic updates and reduced guidance for revenue and EBITDA suggest caution. The Q&A section did not provide additional insights, and potential regulatory challenges add uncertainty. This mixed information leads to a neutral sentiment, as positive financials are offset by concerns about future guidance and risks.
Accuray Incorporated (ARAY) Q2 2026 Earnings Call Transcript
Unknown2-4
The earnings call reveals several negative factors: a decline in net revenue and gross margins, geopolitical tensions affecting product revenue, and reduced revenue guidance. Additionally, workforce reductions and restructuring charges highlight financial strain, while cash flow concerns further dampen sentiment. Although there are some positive aspects, such as service revenue growth and potential new initiatives, the overall picture is negative due to financial challenges and uncertainties.
Accuray Incorporated (ARAY) Q1 2026 Earnings Call Transcript
Unknown11-5
The earnings call summary reveals a decline in net and product revenues, a significant drop in gross margins, and an increased operating loss. Despite a strong order backlog and stable cash position, geopolitical issues in key markets and unclear management responses in the Q&A section contribute to negative sentiment. The guidance suggests a back-loaded fiscal year, but current challenges overshadow potential future improvements. The lack of clarity in management's answers, particularly regarding tariffs and order cancellations, further exacerbates concerns, leading to an overall negative outlook for stock price movement.
Accuray Incorporated (ARAY) Q4 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals mixed results: strong service revenue growth and improved gross margins are positives, but declining product revenue and geopolitical tensions are concerning. Tariff impacts and economic slowdowns add uncertainty. The Q&A highlights optimism for the U.S. market and emerging markets, yet cautiousness remains. Overall, the sentiment is balanced with no clear catalyst for significant short-term stock movement.
ARAY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
